Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial.
Turkova A, White E, Violari A, Mujuru HA, Kekitiinwa AR, Lugemwa A, Kaudha E, Na-Rajsima S, Ahimbisibwe GM, Variavae E, Archary M, Akhalwaya Y, Puthanakit T, Bwakura-Dangarembizi M, Bbuye D, Kasozi M, Liberty A, Königs C, Welch SB, Riault Y, Bamford A, Cressey TR, Musoke P, Kityo C, Ferrand R, Giaquinto C, Rojo P, Gibb DM, Ford D; ODYSSEY trial team.
Turkova A, et al.
Lancet Child Adolesc Health. 2026 Jan 21:S2352-4642(25)00339-6. doi: 10.1016/S2352-4642(25)00339-6. Online ahead of print.
Lancet Child Adolesc Health. 2026.
PMID: 41579881